Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by recurrent episodes of severe swelling in various body parts including hands, feet, abdomen, face, and airway. The swelling or edema occurs due to increased permeability of blood vessels triggered by decreased levels or functionality of C1 inhibitor, a serine protease inhibitor protein. Patients with HAE may experience abdominal pain, nausea or vomiting due to intestinal swelling. Facial swelling can cause breathing difficulty or asphyxiation if laryngeal edema occurs. Attacks are usually unpredictable and can be triggered by minor trauma, stress, or hormonal changes. HAE significantly impacts patients’ quality of life and poses serious health risks including death if laryngeal edema is not treated promptly.
Currently Available Treatment Options and Their Limitations
There are three major categories of drugs available for treating acute HAE attacks – plasma-derived C1-inhibitors, recombinant C1-inhibitors, and bradykinin B2 receptor antagonists (kallikrein inhibitors). Plasma-derived C1-inhibitors like Berinert and Cinryze provide on-demand therapy and are generally safe and effective in treating acute attacks. However, they require intravenous administration and have risk of pathogen transmission. Recombinant C1-inhibitor like Ruconest carries less risk of infection but may cause allergic reactions in some patients. Kallikrein inhibitors like Kalbitor and Firazyr provide alternative on-demand treatment option but are associated with adverse side effects like headache and nausea. Let’s deep dive intoHereditary Angioedema Market
Prophylactic medications approved for long term HAE management include attenuated androgens like danazol and stanozolol. However, prolonged use of androgens can cause serious side effects in both men and women including weight gain, emotional changes, liver toxicity and infertility. PL-3993 is a new bi-specific monoclonal antibody approved for prophylactic therapy, but its high drug acquisition cost remains a limitation. Further, the aforementioned drugs only manage symptoms and do not cure or modify the disease. Overall, current therapies are associated with safety, tolerability, convenience or cost-related issues highlighting the need for novel treatment approaches.
Emerging Role of Plasma-derived C1-inhibitor Concentrates
Plasma-derived C1-inhibitor concentrates are considered the standard of care for acute HAE attacks. Their mechanism of action involves replacement of deficient or dysfunctional C1-inhibitor levels preventing increased vascular permeability and resulting swelling. Key plasma-derived C1-inhibitor replacement therapies include Berinert, Cinryze and newer generation plasma-derived C1-inhibitor products.
Berinert and Cinryze have established safety and efficacy profiles from long term clinical experience. However, they carry a theoretical risk of transmitting blood-borne pathogens. The newer generation plasma-derived C1-inhibitors aim to address this concern. HCP Ruconest is a recombinant C1-inhibitor therapy but has allergic reactions as limitation. Therefore, high purity plasma-derived C1-inhibitor products are promising treatment options due to following advantages:
– Proven mechanism of action and established efficacy in treating HAE attacks.
– Multifold virus inactivation/removal steps during manufacturing ensures high safety profile.
– intravenously administered concentrates work rapidly providing on-demand therapy.
– Potential to reduce treatment cost compared to other biologics with similar efficacy.
– May serve as safe, effective prophylactic therapy with optimized dosing regimens.
Hence, advanced plasma fractionation techniques in newer C1-inhibitors can offer an ideal balance between high efficacy and reassuring safety profile for effective management of HAE.
Market Outlook
The global market for HAE therapeutics is growing rapidly mainly driven by rising disease awareness, new product approvals and favourable reimbursement policies. According to a recent market report published by Coherent Market Insights, the HAE market was valued over $2 billion in 2021 and estimated to exhibit a strong CAGR during 2022-2030. Regionally, North America dominates due to concentration of leading pharmaceutical companies, high diagnosis rate and availability of advanced treatment options. However, countries in Asia Pacific and Latin America are expected to provide lucrative opportunities for players due to growing healthcare investments, economic expansion and increasing patient access to care. Continuous research on novel drug targets, peptide therapeutics and gene therapy holds promise to further expand this therapeutic area. Focus on early diagnosis and management through patient education programs also promotes sustainable market growth.
